Accessibility Menu
PetVivo logo

PetVivo(OTC) PETV

Market Cap$27.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-99%
5 Year-92%
1 Year-22%
1 Month-27%
$0.62
-13.39%
-0.10Today
PetVivo last closing stock price
MetricPriceDate
Last closeUSD 0.622026-07-27
PetVivo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-19.01%USD 0.772026-07-20
1 month-26.64%USD 0.852026-06-26
3 month-21.94%USD 0.802026-04-28
Year to date-45.3%USD 1.142025-12-31
1 year-22.05%USD 0.802025-07-25
3 year-92.66%USD 8.502021-08-10
5 year-92.3%USD 8.102021-07-28
Since inception-99.15%USD 84.442014-03-25

PetVivo Financials at a Glance

Market Cap

$27.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.14M

Net Income (TTM)

-$10.47M

EPS (TTM)

-$0.37

P/E Ratio

-1.97

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Price

$0.62

Volume

38,694

Open

$0.69

Previous Close

$0.62

Daily Range

$0.62 - $0.70

52-Week Range

$0.60 - $1.69

Estimated Earnings Date

Aug 13, 2026

PETV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PetVivo

PetVivo makes medical devices for animals, mainly dogs and horses. Its products help manage joint pain and lameness, improving animal mobility. Veterinarians use these solutions to treat conditions like osteoarthritis in pets.

Products and Services

  • Spryng ($148,243 of Q1 FY2026 revenue): Injection for joint pain in dogs and horses, used by veterinarians.
  • Precise PRP ($149,257 of Q1 FY2026 revenue): Platelet-rich plasma therapy for animal joint health, licensed from VetStem.
  • Therapeutic Device Pipeline: Seventeen products in development for animal and human health applications.
  • Licensing and Patents: Nineteen patents covering biomaterials, production, and use methods.

Growth and Expansion

  • Signed exclusive licensing deal with VetStem for Precise PRP in February 2025.
  • Ended distribution with MWI in March 2025 and Covetrus in February 2025; partnered with Vedco and Clipper Distributing in December 2024.
  • Planning a second manufacturing facility to increase production and research capacity.

What Makes PetVivo Stand Out

PetVivo uses natural biomaterials to mimic animal cartilage, aiming for better compatibility than synthetic options. Its main product, Spryng, targets the root causes of joint pain, not just symptoms. The company relies on distribution partners and in-house manufacturing to reach veterinarians across the U.S.

Five Things You Need to Know

  • Revenue was $297,500 in Q1 FY2026, up 140.4% from Q1 FY2025.
  • Gross profit reached $186,726 in Q1 FY2026, up 68.6% year-over-year.
  • Operating loss was $(2.0) million in Q1 FY2026, up 9.8% from Q1 FY2025.
  • Net loss was $(2.3) million in Q1 FY2026, down 12.9% from Q1 FY2025.

Bottom Line

PetVivo has shifted its distribution strategy and expanded its product line. The company continues to focus on innovation in animal health, but faces ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

22

CEO

John Lai

Website

www.petvivo.com

Headquarters

Edina, MN 55439, US

PETV Financials

Key Financial Metrics (TTM)

Gross Margin

66.11%

Operating Margin

-706.28%

Net Income Margin

-917.45%

Return on Equity

-310.51%

Return on Capital

-313.05%

Return on Assets

-292.83%

Earnings Yield

-50.76%

Dividend Yield

0.00%

Payout Ratio

-3.58%

Stock Overview

Market Cap

$27.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.59M

Volume

38.69K

Avg. Volume

9.42K

Financials (TTM)

Gross Profit

$754.75K

Operating Income

-$8.06M

EBITDA

-$8.86M

Operating Cash Flow

-$6.11M

Capital Expenditure

-$15.39K

Free Cash Flow

-$6.12M

Cash & ST Invst.

$350.78K

Total Debt

$376.16K

PetVivo Performance Analysis

PetVivo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 917,162693.5%
20242024-03-31USD 968,7065.6%
20252025-03-31USD 1,132,53316.9%
20262026-03-31USD 1,141,6070.8%
PetVivo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3032.4%
Q22025-09-301.9%
Q32025-12-31-5.7%
Q42026-03-31-11.0%
PetVivo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -0.8549.0%
20242024-03-31USD -0.78-8.0%
20252025-03-31USD -0.41-47.7%
20262026-03-31USD -0.36-12.0%
PetVivo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3019.8%
Q22025-09-30-14.2%
Q32025-12-3137.5%
Q42026-03-31-27.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$254.72K

+13.3%

Gross Profit

$203.26K

+11.2%

Gross Margin

79.80%

N/A

Market Cap

$27.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.23M

N/A

Employees

22

N/A

Net Income

-$2.96M

-22.5%

EBITDA

-$2.83M

-54.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$350.78K

-7.1%

Total Debt

$376.16K

-87.0%

Accounts Receivable

$700.84K

-84.3%

Inventory

$538.37K

+66.4%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$376.16K

-82.1%

Return on Assets

-2.93%

N/A

Return on Invested Capital

-3.67%

N/A

Free Cash Flow

-$820.12K

+53.2%

Operating Cash Flow

-$812.38K

+34.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PVCTProvectus Biopharmaceuticals, Inc.
$0.06+0.14%
POSCPositron Corporation
$1.57-6.55%
EXHIExlites Holdings International, Inc.
$0.40+11.11%
IPDQFImpediMed Limited
$0.00-40.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TAT&T
$24.42+0.01%

Questions About PETV

What is the current price of PetVivo?

PetVivo is trading at $0.62 per share.

What is the 52-week range for PetVivo?

Over the past 52 weeks, PetVivo has traded between $0.60 and $1.69.

How much debt does PetVivo have?

As of the most recent reporting period, PetVivo reported total debt of $376.16K.

How much cash does PetVivo have on hand?

PetVivo reported $200.78K in cash and cash equivalents in its most recent financial results.

What is PetVivo’s dividend yield?

PetVivo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services